Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 7/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.46 |
| ▸ | BUB1 | O43683 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.46 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1543059 | 1.00 | HPGDS (0.61) | HPGDSGABRA5MAP4K4CYP2C9MAPK14 | |
| SCHEMBL1543315 | 0.90 | HPGDS (0.56) | HPGDSGABRA5MAP4K4GRM5USP30 | |
| SCHEMBL1543508 | 0.90 | HPGDS (0.56) | HPGDSGABRA5MAP4K4GRM5USP30 | |
| SCHEMBL1543312 | 0.90 | HPGDS (0.56) | HPGDSGABRA5MAP4K4GRM5USP30 | |
| SCHEMBL1543314 | 0.90 | HPGDS (0.56) | HPGDSGABRA5MAP4K4GRM5USP30 | |
| SCHEMBL1543507 | 0.90 | HPGDS (0.56) | HPGDSGABRA5MAP4K4GRM5USP30 | |
| SCHEMBL2982039 | 0.88 | HPGDS (0.55) | HPGDSGABRA5MAP4K4CYP2C9MAPK14 | |
| SCHEMBL1543340 | 0.87 | HPGDS (0.74) | HPGDSGABRA5MAP4K4CYP2C9MAPK14 | |
| SCHEMBL13572496 | 0.85 | HPGDS (0.62) | HPGDSGABRA5MAP4K4CYP2C9MAPK14 | |
| SCHEMBL13240634 | 0.85 | HPGDS (0.64) | HPGDSGABRA5MAP4K4CYP2C9MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885GABRA5 1938/4885MAP4K4 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.